Pharma Mar Past Earnings Performance
Past criteria checks 1/6
Pharma Mar's earnings have been declining at an average annual rate of -24.8%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been declining at an average rate of 1.3% per year. Pharma Mar's return on equity is 0.3%, and it has net margins of 0.4%.
Key information
-24.8%
Earnings growth rate
-35.5%
EPS growth rate
Biotechs Industry Growth | 11.5% |
Revenue growth rate | -1.3% |
Return on equity | 0.3% |
Net Margin | 0.4% |
Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Pharma Mar makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Sep 24 | 167 | 1 | 45 | 105 |
30 Jun 24 | 159 | -2 | 44 | 104 |
31 Mar 24 | 162 | 2 | 43 | 105 |
31 Dec 23 | 158 | 1 | 42 | 99 |
30 Sep 23 | 168 | 14 | 40 | 95 |
30 Jun 23 | 175 | 21 | 43 | 90 |
31 Mar 23 | 177 | 29 | 42 | 85 |
31 Dec 22 | 196 | 49 | 43 | 83 |
30 Sep 22 | 235 | 79 | 48 | 85 |
30 Jun 22 | 233 | 85 | 42 | 84 |
31 Mar 22 | 232 | 91 | 41 | 76 |
31 Dec 21 | 230 | 93 | 40 | 72 |
30 Sep 21 | 188 | 63 | 34 | 61 |
30 Jun 21 | 200 | 67 | 35 | 58 |
31 Mar 21 | 222 | 91 | 35 | 56 |
31 Dec 20 | 270 | 137 | 36 | 54 |
30 Sep 20 | 246 | 147 | 37 | 48 |
30 Jun 20 | 214 | 124 | 38 | 47 |
31 Mar 20 | 166 | 72 | 39 | 48 |
31 Dec 19 | 86 | -9 | 38 | 51 |
30 Sep 19 | 136 | -27 | 58 | 58 |
30 Jun 19 | 84 | -37 | 38 | 61 |
31 Mar 19 | 154 | -24 | 59 | 69 |
31 Dec 18 | 109 | -17 | 39 | 74 |
30 Sep 18 | 189 | -16 | 66 | 80 |
30 Jun 18 | 128 | -20 | 44 | 119 |
31 Mar 18 | 179 | -26 | 65 | 79 |
31 Dec 17 | 159 | -28 | 58 | 79 |
30 Sep 17 | 182 | -22 | 67 | 77 |
30 Jun 17 | 186 | -18 | 74 | 78 |
31 Mar 17 | 184 | -19 | 67 | 78 |
31 Dec 16 | 181 | -24 | 68 | 78 |
30 Sep 16 | 187 | -18 | 68 | 75 |
30 Jun 16 | 188 | -10 | 71 | 60 |
31 Mar 16 | 190 | -7 | 70 | 66 |
31 Dec 15 | 194 | 7 | 69 | 60 |
31 Dec 14 | 175 | 13 | 60 | 46 |
31 Dec 13 | 74 | 12 | 59 | 0 |
Quality Earnings: 0RC6 has a high level of non-cash earnings.
Growing Profit Margin: 0RC6's current net profit margins (0.4%) are lower than last year (8.3%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 0RC6 has become profitable over the past 5 years, growing earnings by -24.8% per year.
Accelerating Growth: 0RC6's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 0RC6 had negative earnings growth (-95.5%) over the past year, making it difficult to compare to the Biotechs industry average (-18.2%).
Return on Equity
High ROE: 0RC6's Return on Equity (0.3%) is considered low.